Ex Vivo Lung Perfusion with β-Nicotinamide Adenine Dinucleotide (NAD<sup>+</sup>) Improves Ischemic Lung Function.

Antioxidants (Basel) · 2022 · PMC9137530 · PMID 35624707

Europe PMC DOI

hedged sentences

0.1240

closest p · 2.5× alpha

0.2510

boldest claim

The sentences

showed a trendp = 0.124not close (p > 0.1)

Maximal flow was reduced and showed a trend of being more obstructed with 200 μM NAD + flush ( p = 0.124, Figure 3 C) than in the control group, whereas 100 μM NAD + flush was comparable ( p = 0.390, Figure 3 C).

also in 53,322 other papers

a slight trendp = 0.251not close (p > 0.1)

Moreover, there was a slight trend of less pro-inflammatory IL-12 ( p = 0.251) and anti-inflammatory IL-4 ( p = 0.317).

also in 4,078 other papers

a strong trendno p-value reported

a weak trendno p-value reported

However, it is questionable whether these effects were already present during the few hours of exposure of the lungs to NAD + during our 4 h EVLP experiments, as we detected only a strong trend of higher INFy and a weak trend of higher IL-4 in the perfusate.

also in 5,725 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.